Javier Martínez Pérez

Statistics

Publications

Citations

1.2K

H-Index

Active since

2013

Affiliations

Alnylam Pharmaceuticals (United States)(Current)

Assistance Publique – Hôpitaux de Paris

Université Paris-Saclay

Bicêtre Hospital

University College London

Javier Martínez Pérez is an author at Alnylam Pharmaceuticals (United States) specializing in hereditary amyloidosis, gene therapy, and rna interference therapeutics.

ORCID

Publications per year

2013–2025

Publications

Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis

Teresa Coelho, David Adams, Ana Silva et al. · New England Journal of Medicine · 2013 · 961 citations · Full text

Life Sciences, Molecular Biology, Molecular Medicine +15

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

David Adams, Michael Polydefkis, Alejandra González‐Duarte et al. · The Lancet Neurology · 2020 · 156 citations

Medicine, Neurology, Pharmacotherapy +14

Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy

David Adams, Jonas Wixner, Michael Polydefkis et al. · JAMA Neurology · 2025 · 31 citations · Full text

Medicine, Neurology, Pharmacotherapy +13

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Laura Obici, Senda Ajroud‐Driss, Kon‐Ping Lin et al. · Neurology and Therapy · 2023 · 20 citations · Full text

Medicine, Neurology, Pharmacotherapy +11

1–4 of 4